NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of NeuroVive Pharmaceutical (OTCMKTS:NEVPF) from a buy rating to a hold rating in a report published on Tuesday morning, reports.

According to Zacks, “NeuroVive Pharmaceutical AB is engaged in the research, discovery and development of mitochondrial-protecting pharmaceuticals. The company’s drug candidate consists of CicloMulsion(R) and NeuroSTAT(R) in clinical phases. CicloMulsion(R) is being studied for preoperative treatment of acute kidney injury coincident with major surgery and NeuroSTAT(R) is being studied for treating traumatic brain injury. NeuroVive Pharmaceutical AB is headquartered in Lund, Sweden. “

Shares of NEVPF stock opened at $0.20 on Tuesday. NeuroVive Pharmaceutical has a 1 year low of $0.10 and a 1 year high of $0.60. The firm’s fifty day moving average price is $0.18 and its two-hundred day moving average price is $0.16. The firm has a market capitalization of $13.08 million, a P/E ratio of -1.82 and a beta of 1.91.

About NeuroVive Pharmaceutical

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases.

Read More: Why are percentage gainers important?

Get a free copy of the Zacks research report on NeuroVive Pharmaceutical (NEVPF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with's FREE daily email newsletter.